CD8+ cytotoxic lymphocytes (CTL) capable of directly killing tumour cells are considered as the prime target of immunotherapy but CD4+ T helper cells and B cells can also contribute to revival of anti-tumour immunity following checkpoint inhibition (1–4). Here, CD4 is linked to neoplasm.